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Abstract
Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For
patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim
was to compare the prognostic performance of the scores and to arrive at an evidence-based score recommendation. In 2949
patients not involved in any score development, higher hazard ratios and concordance indices in any comparison
demonstrated the best discrimination of long-term survival with the ELTS score. In a second step, of 5154 patients analyzed
to investigate risk group classification differences, 23% (n= 1197) were allocated to high-risk by the Sokal score. Of the
1197 Sokal high-risk patients, 56% were non-high-risk according to the ELTS score and had a significantly more favorable
long-term survival prognosis than the 526 high-risk patients according to both scores. The Sokal score identified too many
patients as high-risk and relatively few (40%) as low-risk (versus 60% with the ELTS score). Inappropriate risk classification
jeopardizes optimal treatment selection. The ELTS score outperformed the Sokal score, the Euro, and the EUTOS score
regarding risk group discrimination. The recent recommendation of the European LeukemiaNet for preferred use of the
ELTS score was supported with significant statistical evidence.
Introduction
For patients with Philadelphia chromosome-positive (Ph+)
chronic-phase chronic myeloid leukemia (CML), four baseline
prognostic scores were addressed by the most recent European
LeukemiaNet (ELN) recommendations [1]. First, in 1984, the
Sokal score was developed to allocate chemotherapy-treated
patients into three risk groups of approximately equal size
predicting significantly different overall survival (OS) prob-
abilities [2, 3]. In 1998, the Euro score was proposed to dis-
criminate OS between three risk groups of patients treated
with interferon alpha [2, 4]. Using data on patients who were
treated with imatinib, in 2011 the European Treatment and
Outcome Study for CML (EUTOS) score identified two risk
groups with significantly different probabilities of complete
cytogenetic response after 18 months of therapy [2, 5], and in
2016, the EUTOS Long-Term Survival (ELTS) score was
introduced in order to distinguish three risk groups with sig-
nificantly different probabilities of dying of CML [6].
Regarding its primary endpoint, the ELTS score was
successfully validated in an independent patient sample and
showed a superior risk group discrimination compared with
the Sokal score [6]. The Sokal score identified 41% of
patients as low-risk and 23% as high-risk. The ELTS score,
however, identified an absolute proportion of 20% more
low-risk patients and 11% fewer high-risk patients [6]. Ten
years after the start of first-line imatinib treatment, prob-
abilities of dying of CML were 6 and 8% according to
Hehlmann et al. [7] and Molica et al. [8], respectively.
These results are rather in line with 12% high-risk patients
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as suggested by the ELTS score than with 23% high-risk
patients as defined by the Sokal score.
The Sokal score has been particularly popular [1]. This
may have been due to the preference for risk groups of more
equal size, but a more likely reason was lack of acceptance
of newer scores. Accordingly, analyses established in major
randomized trials continued to be risk stratified by the Sokal
score [9–13]. Here, some association between Sokal risk
group and clinical outcome was identified [9–11, 13]. While
the most recent ELN recommendations advise risk assess-
ment with the ELTS score [1], it is hence still essential to
provide convincing data-based evidence when arguing for
its preference over others.
The aim of this work was to compare the prognostic
discrimination between the Sokal score [3] and the ELTS
score [6] and to provide an evidence-based recommendation
of which score to apply. Although the focus was on the
comparison between the enduringly popular Sokal score
and the relatively new ELTS score, results for the Euro and
the EUTOS score are also provided.
Patients and methods
Patients
In 2007, a registry of CML patients was established by the
ELN and maintained within the EUTOS framework [5].
This registry contains individual data on adult patients who
were prospectively enrolled between 2002 and 2006, either
within or outwith a clinical trial (in-study and out-study
sections, respectively) [5, 14]. Further patient eligibility
criteria for both registry sections were diagnosis of Ph+
and/or BCR-ABL1-positive CML in chronic phase, no
transcript type other than b2a2 and/or b3a2, and any form of
imatinib-based treatment within 6 months from diagnosis
[5, 14]. In accordance with these criteria, 2205 patients with
data on all variables of each score were retrieved from the
in-study section [6]. While data on the in-study patients
remained unchanged for the present report, follow-up was
updated in 2016 for most patients in the out-study section.
Two of the 1120 cases reported earlier [6] were identified as
double data entries and were left out from further analyses.
A third population-based component of the registry accu-
mulated data on adult patients newly diagnosed between
2008 and 2013 [15]. Apart from adulthood, Ph+ and/or
BCR-ABL1-positive CML was the only inclusion criterion
[15]. For the population-based section, the same inclusion
criteria were chosen as for the two other sections, except
that the restriction on patients with first-line imatinib
treatment within 6 months from diagnosis was relaxed. Of
the 1831 patients finally included, 68 had received first-line
dasatinib (4%) and 247 (14%) first-line nilotinib treatment;
similarly for 78 patients (4%), treatment start was later than
6 months after diagnosis. Relaxation of the two criteria was
based on the observation that both had no association with
survival probabilities in the population-based section.
At first, the score comparisons were based on the 2949
patients with data entirely independent of any score devel-
opment. In a second step, data of the in-study sample used
for the development of the ELTS score were added. Only
after addition of these patients was the number of events
sufficient in order to assess the adequacy of low- or high-
risk categorization between the different scores.
Definitions and endpoints
OS time was calculated from the start date of tyrosine
kinase inhibitor (TKI) treatment to death or to the latest
follow-up date. Progression-free survival time was calcu-
lated like survival time but ended with the observation of
progression. Progression was defined by the observation of
accelerated phase or blast crisis, with both phases deter-
mined according to the ELN criteria [16]. Chronic phase
was defined by the absence of progression [16]. Only death
after recorded disease progression was regarded as “death
due to CML”. Death without prior disease progression was
rated as “death unrelated to CML”. For details regarding the
calculation of the Sokal [3], the ELTS [6], the Euro [4], and
the EUTOS score [5], see Supplementary Table 1.
Statistical analysis
OS probabilities were calculated by the Kaplan–Meier
method, and the hazards ratios (HRs) for dying from any
cause were calculated by the Cox regression model [17].
When differentiating competing causes of death, cumulative
incidence probabilities of dying of CML were obtained using
the Aalen–Johansen estimator [18, 19] and the subdistribution
hazards ratios (SHRs) for dying of CML were obtained using
the Fine–Gray model [20]. Like the Aalen–Johansen esti-
mator, the Fine–Gray model and its SHRs consider death
unrelated to CML as the competing event to death due to
CML, the event of interest. Both the hazards from the Cox
model as well as the SHRs were compared by the Wald test.
To assess discrimination of prognostic models, concordance
probabilities were estimated using the truncated concordance
index suggested by Wolbers et al. [21]. For the description of
discrimination ability over time, the truncation times 1, 5, and
10 years were considered. A higher concordance index hints
at a better discrimination of the survival outcome. With
indices greater than 50, a prognostic model provides clinically
useful information different from chance; the closer to 100,
the more supportive the model is.
Lauseker and Zu Eulenburg elucidated that the use of the
competing risk model leads to biased cumulative incidence
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probability estimates when the censoring mechanism differs
between status, e.g., between patients in chronic- or pro-
gressive- phase [22]. In the case of a status-dependent cen-
soring mechanism, they showed that the progressive illness-
death model should be preferred over the competing risk
model (see Supplementary Fig. 1 for a comparison of the
models). Accordingly, in the presence of status-dependent
censoring, the ability to discriminate probabilities of dying of
CML was additionally investigated with the progressive
illness-death model. For this, the associations between risk
group and transition probabilities were considered [23].
For the two-sided P values, the unadjusted significance
level of 0.05 was applied for all statistical tests. Estimates
were presented with 95% confidence interval (95% CI). More
on statistical methods is given in the Supplementary appendix.
Results
Prognostic discrimination in 2949 patients from the
combined out-study and population-based sections
For the out-study data, origin and details as well as the
validation of a significant discrimination of the probabilities
of dying of CML by the ELTS score have been previously
described [6, 14].
Adding the population-based section to the 1118 out-
study patients, a validation sample of 2949 patients inde-
pendent of any score development was achieved. The
combined sample consisted of 52% males. Median age of
the 2949 patients was 52 years (range: 18–91 years) and
median follow-up was 3.3 years (range: 0.01–12.6 years).
Altogether, 236 patients died, of whom 89 (38%) died of
CML. Six-year OS probability in the 2949 patients was
88% (95% CI: 86–89%), and 6-year probability of death
due to CML was 5% (95% CI: 4–6%).
Prognostic discrimination of cumulative incidence
probabilities of dying of CML
The high-risk group of the Sokal score (n= 698, 24%),
though not the intermediate-risk group (n= 1177, 40%),
had significantly higher probabilities of dying because of
CML than the low-risk group (n= 1074, 36%), P < 0.0001
and P= 0.0835, respectively (Fig. 1a). The corresponding
SHRs were 3.559 (95% CI: 2.030–6.240) and 1.668 (95%
CI: 0.934–2.978). The concordance indices at 1, 5, and 10
years were 59.7, 62.4, and 63.3, respectively.
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Low risk, n = 1074, 6−year probability: 2%, 95% CI: 1−4%
Years after start of TKI
Number of patients still at risk (n) at different years of observation Number of patients still at risk (n) at different years of observation
Intermediate risk, n = 1177, 6−year probability: 5%, 95% CI: 3−7%
High risk, n = 698, 6−year probability: 9%, 95% CI: 6−12%
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Low risk, n = 1688, 6−year probability: 3%, 95% CI: 2−4%
Years after start of TKI
Intermediate risk, n = 853, 6−year prob.: 5%, 95% CI: 3−7%
High risk, n = 408, 6−year probability: 15%, 95% CI: 9−22%
b
Year 0 3 6 9 
Low risk, n 1074 600 203 57 
Intermediate risk, n 1177 598 175 50 
High risk, n 698 341 82 19 
Year 0 3 6 9 
Low risk, n 1688 935 302 86 
Intermediate risk, n 853 427 115 34 
High risk, n 408 177 43 6 
Fig. 1 Cumulative incidence probabilities of dying because of
CML in 2949 patients from the combined out-study and
population-based registry sections. a Stratified for the risk groups
according to the Sokal score and b Stratified for the risk groups
according to the ELTS score. At 3, 6, and 9 years, horizontal crossbars
indicate the upper and lower limit of the 95% confidence interval (CI)
for the estimated probability. a The high-risk group of the Sokal score,
though not the intermediate-risk group, had significantly higher
probabilities of dying because of CML than the low-risk group,
P < 0.0001 and P= 0.0835, respectively. The corresponding SHRs
were 3.559 (95% CI: 2.030–6.240) and 1.668 (95% CI: 0.934–2.978).
The concordance indices at 1, 5, and 10 years were 59.7, 62.4, and
63.3, respectively. b The intermediate- and high-risk groups of the
ELTS score had significantly higher probabilities of dying due to CML
than the low-risk group with P= 0.0031 and P < 0.0001, respectively.
The corresponding hazard ratios were 2.203 (95% CI: 1.306–3.718)
and 5.646 (95% CI: 3.397–9.387). The concordance indices at 1, 5,
and 10 years were 68.0, 66.0, and 68.1, respectively.
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With the ELTS score, both the intermediate- (n= 853,
29%; P= 0.0031) and the high-risk group (n= 408, 14%;
P < 0.0001) had significantly higher probabilities of dying
because of CML than the low-risk group (n= 1688, 57%,
Fig. 1b). The corresponding SHRs were 2.203 (95% CI:
1.306–3.718) and 5.646 (95% CI: 3.397–9.387). The
concordance indices at 1, 5, and 10 years were 68.0, 66.0,
and 68.1. Discrimination abilities were worse with the
Euro and the EUTOS score (Supplementary Fig. 2a–b).
The Euro score was not able to find a significant dis-
crimination between the intermediate- and the low-risk
group, and the EUTOS score was not able to find a sig-
nificant discrimination between the low- and the high-
risk group.
State-dependent censoring: application of the progressive
illness-death model
In the combined out-study/population-based sample, 153
patients (5%) experienced progression. The cumulative
hazard of censoring was significantly higher for patients in
progressive phase (P < 0.0001). Differences in the state
occupation probabilities for death after progression were
observed (Supplementary Fig. 3). After 8 years, the prob-
ability of death after progression was 7.3% with the
progressive illness-death model and 5.7% with the com-
peting risk model. In contrast, for death without progression
probability differences were small (10.5 and 10.6%).
The estimated associations between risk group and
transition probabilities in the progressive illness-death
model are shown in Supplementary Table 2. Compared
with the ELTS score, none of the three other prognostic
models displayed a better discrimination of transition
probabilities (Supplementary Table 2).
Prognostic discrimination of OS probabilities
The intermediate- (HR: 2.256 [95% CI: 1.590–3.201] and
high-risk groups (HR: 3.384 [95% CI: 2.359–4.852] of the
Sokal score had significantly lower survival probabilities
than the low-risk group with both P < 0.0001 (Fig. 2a). The
concordance indices at 1, 5, and 10 years were 62.9, 62.0,
and 61.3, respectively.
With slightly higher hazard ratios and concordance
indices of 65.6, 64.0, and 64.0 at 1, 5, and 10 years, the
same was observed for the intermediate- (HR: 2.479 [95%
CI: 1.836–3.345] and high-risk groups (HR: 4.012 [95% CI:
2.884–5.582] of the ELTS score (Fig. 2b).
While the HRs and the concordances indices of the Euro
score were slightly less favorable than the ELTS score, the
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Years after start of TKI
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Low risk, n = 1074, 6−year probability: 94%, 95% CI: 92−96%
Intermediate risk, n = 1177, 6−year prob.: 86%, 95% CI: 82−89%
High risk, n = 698, 6−year probability: 81%, 95% CI: 76−85%
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High risk, n = 408, 6−year probability: 75%, 95% CI: 66−81%
Year 0 3 6 9 
Low risk, n 1074 600 203 57 
Intermediate risk, n 1177 598 175 50 
High risk, n 698 341 82 19 
Year 0 3 6 9 
Low risk, n 1688 935 302 86 
Intermediate risk, n 853 427 115 34 
High risk, n 408 177 43 6 
Number of patients still at risk (n) at different years of observation Number of patients still at risk (n) at different years of observation
Fig. 2 Overall survival probabilities in 2949 patients from the
combined out-study and population-based registry sections.
a Stratified for the risk groups according to the Sokal score and
b Stratified for the risk groups according to the ELTS score. At 3, 6,
and 9 years, horizontal crossbars indicate the upper and lower limit of
the 95%-confidence interval (CI) for the estimated probability. a The
intermediate- and high-risk groups of the Sokal score had significantly
lower survival probabilities than the low-risk group with both
P < 0.0001. The corresponding hazard ratios were 2.256 (95% CI:
1.590–3.201) and 3.384 (95% CI: 2.359–4.852). The concordance
indices at 1, 5, and 10 years were 62.9, 62.0, and 61.3, respectively.
b The intermediate- and high-risk groups of the ELTS score had
significantly lower survival probabilities than the low-risk group with
both P < 0.0001. The corresponding hazard ratios were 2.479 (95% CI:
1.836–3.345) and 4.012 (95% CI: 2.884–5.582). The concordance
indices at 1, 5, and 10 years were 65.6, 64.0, and 64.0, respectively.
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EUTOS score failed to discriminate risk groups (Supple-
mentary Fig. 4a–b).
Prognostic discrimination in 5154 patients from all
three combined registry sections
The sample of all three combined registry sections consisted
of 5154 patients with 52% males and a median age of 52
years (range: 18–91 years). With a median follow-up of 5.3
years (range: 0.01–12.6 years), 429 deaths were recorded,
175 (41%) of which were due to CML. Six-year survival
probability of all patients was 90% (95% CI: 89–81%) and
6-year probability of death due to CML was 4% (95%
CI: 4–5%).
Prognostic discrimination of cumulative incidence
probabilities of dying of CML
The intermediate- (n= 1975, 38%) and the high-risk groups
of the Sokal score (n= 1197, 23%) had significantly higher
cumulative incidence probabilities of dying due to CML
than the low-risk group (n= 1982, 38%), P= 0.0088 and
P < 0.0001, respectively (Fig. 3a). The corresponding SHRs
were 1.695 (95% CI: 1.142–2.515) and 3.161 (95% CI:
2.146–4.655). The concordance indices at 1, 5, and 10 years
were 58.8, 62.1, and 62.2.
Of the 1197 patients allocated to high-risk by the Sokal
score, 671 (56%) were classified as non-high-risk by the
ELTS score. Compared with the 526 patients identified as
high-risk by both scores, the cumulative incidence prob-
abilities of dying because of CML were significantly lower for
the 671 ELTS non-high-risk patients (SHR: 0.415 [95% CI:
0.256–0.671], P= 0.0003, Fig. 3b). The concordance indices
at 1, 5, and 10 years were 63.3, 60.8, and 59.9, respectively.
Compared with the low-risk group (n= 3037, 59%), the
cumulative incidence probabilities of dying because of
CML were significantly higher in the intermediate- (n=
1449, 28%, SHR: 2.584 [95% CI: 1.795–3.721]) and the
high-risk groups (n= 668, 13% SHR: 5.667 [95% CI:
3.912–8.209]) of the ELTS score, with both P < 0.0001
(Fig. 4a). The concordance indices at 1, 5, and 10 years
were 69.6, 66.8, and 67.3, respectively.
Of the 3037 patients identified as low-risk by the ELTS
score, the Sokal score allocated 1200 (40%) to non-low-
risk. In relation to the low-risk patients, the cumulative
incidence probabilities of dying of CML of the 1200 Sokal
non-low-risk patients were hardly different (SHR: 1.129
[95% CI: 0.653–1.951], P= 0.6635, Fig. 4b).
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Low risk, n = 1982, 6−year probability: 3%, 95% CI: 2−3%
Years after start of TKI
Intermediate risk, n = 1975, 6−year probability: 4%, 95% CI: 3−5%
High risk, n = 1197, 6−year probability: 8%, 95% CI: 6−10%
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Non−High risk, n = 671, 6−year prob.: 5%, 95% CI: 3−7%
Years after start of TKI
High risk, n = 526, 6−year probability: 12%, 95% CI: 9−16%
b
Number of patients still at risk (n) at different years of observation Number of patients still at risk (n) at different years of observation
Year 0 3 6 9 
Low risk, n 1982 1432 741 79 
Intermediate risk, n 1975 1328 621 74 
High risk, n 1197 768 320 32 
Year 0 3 6 9 
Non-high risk, n 671 452 192 20 
High risk, n 526 316 128 12 
Fig. 3 Cumulative incidence probabilities of dying due to CML in
5154 patients from the combined in-study, out-study, and
population-based registry sections. a Stratified for the risk groups
according to the Sokal score and b with the 1197 high-risk patients
according to the Sokal score stratified for non-high-risk and high-risk
according to the ELTS Score. At 3, 6, and 9 years, horizontal crossbars
indicate the upper and lower limit of the 95% confidence interval (CI)
for the estimated probability. a The intermediate- and high-risk groups
of the Sokal score had significantly higher probabilities of dying due to
CML than the low-risk group with P= 0.0088 and P < 0.0001,
respectively. The corresponding hazard ratios were 1.695 (95% CI:
1.142–2.515) and 3.161 (95% CI: 2.146–4.655). The concordance
indices at 1, 5, and 10 years were 58.8, 62.1, and 62.2, respectively.
b The high-risk group according to both scores had significantly higher
probabilities of dying due to CML than the non-high-risk group
identified by the ELTS score, P= 0.0003. The corresponding hazard
ratio was 0.415 (95% CI: 0.256–0.671). The concordance indices at 1,
5, and 10 years were 63.3, 60.8, and 59.9, respectively.
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With reference to its low-risk group, the Euro score
identified significantly higher cumulative incidence prob-
abilities of dying because of CML in high-risk patients (P <
0.0001) but failed to do so in patients with intermediate risk
(P= 0.3768, Supplementary Fig. 5a). The EUTOS score
found significantly higher cumulative incidence prob-
abilities of dying in high-risk patients (P= 0.0002, Sup-
plementary Fig. 5b).
No state-dependent censoring in the 5154 patients from all
three combined registry sections
In the patient sample made up of data from all three registry
sections, 275 patients had disease progression (5%). The
cumulative hazard of censoring was not significantly dif-
ferent between the phases (P= 0.2868) and differences in
the state occupation probabilities between the statistical
models were not of any relevance (Supplementary Fig. 6).
Prognostic discrimination of OS probabilities
The intermediate- (HR: 2.049 [95% CI: 1.607–2.611]) and
high-risk groups (HR: 2.596 [95% CI: 2.009–3.355]) of the
Sokal score had significantly lower survival probabilities
than the low-risk group, with both P < 0.0001 (Fig. 5a). The
concordance indices at 1, 5, and 10 years were 61.2, 60.6,
and 59.7.
The 526 high-risk patients according to both scores had
significantly lower survival probabilities than the 671 non-
high-risk patients identified by the ELTS score (P= 0.0041,
Fig. 5b). The HR for non-high- to high-risk patients was
0.615 (95% CI: 0.442–0.857); concordance indices at 1, 5,
and 10 years were 56.5, 55.6, and 55.4
With reference to the low-risk group of the ELTS score,
the HRs of the intermediate- and high-risk groups were
2.631 (95% CI: 2.116–3.273) and 3.675 (95% CI:
2.861–4.720), respectively (both P < 0.0001, Fig. 6a) and
the concordance indices at 1, 5, and 10 years were 66.6,
63.8, and 63.7.
The 1200 non-low-risk patients identified by the Sokal
score had significantly lower survival probabilities than the
1837 low-risk patients according to both scores (P=
0.0147, Fig. 6b). The corresponding hazard ratio was 1.490
(95% CI: 1.082–2.053). The concordance indices at 1, 5,
and 10 years were 49.8, 54.4, and 54.4, respectively.
Like the Sokal and ELTS scores, the Euro score sug-
gested an intermediate- and a high-risk group with sig-
nificantly lower OS probabilities compared with low-risk
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Low risk, n = 3037, 6−year probability: 2%, 95% CI: 2−3%
Years after start of TKI
Intermediate risk, n = 1449, 6−year probability: 5%, 95% CI: 4−7%
High risk, n = 668, 6−year probability: 12%, 95% CI: 9−15%
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Low risk, n = 1837, 6−year probability: 2%, 95% CI: 1−3%
Years after start of TKI
Non−Low risk, n = 1200, 6−year probability: 2%, 95% CI: 2−4%
b
Year 0 3 6 9 
Low risk, n 3037 2180 1084 120 
Intermediate risk, n 1449 955 431 51 
High risk, n 668 393 167 14 
Year 0 3 6 9 
Low risk, n 1837 1338 694 75 
Non-low risk, n 1200 842 390 45 
Number of patients still at risk (n) at different years of observation Number of patients still at risk (n) at different years of observation
Fig. 4 Cumulative incidence probabilities of dying due to CML in
5154 patients from the combined in-study, out-study, and
population-based registry sections. a Stratified for the risk
groups according to the ELTS score and b with the 3037 low-risk
patients according to the ELTS score stratified for low-risk and non-
low-risk according to the Sokal Score. At 3, 6, and 9 years, horizontal
crossbars indicate the upper and lower limit of the 95% confidence
interval (CI) for the estimated probability. a The intermediate- and
high-risk groups of the ELTS score had significantly higher
probabilities of dying due to CML than the low-risk group with both P
< 0.0001. The corresponding hazard ratios were 2.584 (95% CI:
1.795–3.721) and 5.667 (95% CI: 3.912–8.209). The concordance
indices at 1, 5, and 10 years were 69.6, 66.8, and 67.3, respectively.
b The non-low-risk group identified by the Sokal score had no sig-
nificantly different probabilities of dying due to CML than the low-risk
group according to both scores, P= 0.6635. The corresponding hazard
ratio was 1.129 (95% CI: 0.653–1.951). The concordance indices at
1, 5, and 10 years were not analysable, 47.6, and 47.7, respectively.
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in. . . 2143
patients (both P < 0.0001, Supplementary Fig. 7a) while
the EUTOS score failed to discriminate significantly
different OS probabilities (P= 0.0739, Supplementary
Fig. 7b).
Discussion
Although first described over 30 years ago, the Sokal score
remains popular for risk group discrimination, despite
suggesting that, at diagnosis, more than 20% of chronic-
phase patients are at high-risk with respect to OS—even in
the presence of TKIs—and despite the availability of the
ELTS score developed in imatinib-treated patients [6]. The
main objective of this work is to provide evidence-based
information on what score should be preferred, comparing
prognostic discrimination performance between the Sokal
and the ELTS score.
To pay tribute to the improved survival evoked by TKI
therapy, when developing the ELTS score, the focus was
the probabilities of dying of CML (i.e., after progression)
rather than dying of any cause. In 2949 patients independent
of any score development, unlike the ELTS score, the Sokal
score failed to recognize significantly different cumulative
incidence probabilities of dying of CML between inter-
mediate- and low-risk patients. Secondly, in relation to the
low-risk group, the SHRs as well as the concordance indi-
ces were always higher with the ELTS score indicating a
better discrimination than with the Sokal score. This result
was also observed in the combined sample of 5154 patients
from all three registries.
A limitation of the prognostic discrimination compar-
isons in the combined out-study/population-based sample of
2949 patients was the probable state-dependent censoring.
This led to slightly biased cumulative incidence prob-
abilities for death after progression when compared with the
gold standard of the progressive illness-death model.
Applying the illness-death model, the significantly different
hazards for the transitions into progression and into death in
chronic phase confirmed a satisfactory discrimination
between the risk groups of the ELTS score (Supplementary
Table 2). No other score provided a better discrimination of
risk groups.
In the samples of 2949 and 5154 patients, for both the
Sokal and the ELTS score, all pairwise risk group com-
parisons led to significant differences in OS probabilities.
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Years after start of TKI
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Low risk, n = 1982, 6−year probability: 94%, 95% CI: 93−95%
Intermediate risk, n = 1975, 6−year prob.: 88%, 95% CI: 87−90%
High risk, n = 1197, 6−year probability: 85%, 95% CI: 82−87%
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Non−High risk, n = 671, 6−year prob.: 88%, 95% CI: 85−91%
High risk, n = 526, 6−year probability: 81%, 95% CI: 76−85%
Year 0 3 6 9 
Low risk, n 1982 1432 741 79 
Intermediate risk, n 1975 1328 621 74 
High risk, n 1197 768 320 32 
Year 0 3 6 9 
Non-high risk, n 671 452 192 20 
High risk, n 526 316 128 12 
Number of patients still at risk (n) at different years of observation Number of patients still at risk (n) at different years of observation
Fig. 5 Overall survival probabilities in 5154 patients from the
combined in-study, out-study, and population-based registry sec-
tions. a Stratified for the risk groups according to the Sokal score and
b with the 1197 high-risk patients according to the Sokal score stra-
tified for non-high-risk and high-risk according to the ELTS Score. At
3, 6, and 9 years, horizontal crossbars indicate the upper and lower
limit of the 95%-confidence interval (CI) for the estimated probability.
a The intermediate- and high-risk groups of the Sokal score had sig-
nificantly lower survival probabilities than the low-risk group with
both P < 0.0001. The corresponding hazard ratios were 2.049 (95% CI:
1.607–2.611) and 2.596 (95% CI: 2.009–3.355). The concordance
indices at 1, 5, and 10 years were 61.2, 60.6, and 59.7, respectively.
b The high-risk group according to both scores had significantly lower
survival probabilities than the non-high-risk group identified by the
ELTS score, P= 0.0041. The hazard ratio for non-high- to high-risk
patients was 0.615 (95% CI: 0.442–0.857). The concordance indices at
1, 5, and 10 years were 56.5, 55.6, and 55.4, respectively.
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Again, in any case, the HRs as well as the concordance
indices were always higher with the ELTS score than with
the Sokal score.
While the sample of 2949 independent patients guaran-
teed an unbiased comparison between the Sokal and the
ELTS score, the sample of 5154 patients was needed for
provision of event numbers high enough to investigate risk
group classification differences between the scores. Of 1197
patients allocated to high-risk by the Sokal score, the ELTS
score classified 56% as non-high-risk. Compared with the
526 high-risk patients according to both scores, the cumu-
lative incidences of dying of CML were significantly lower
and OS probabilities were significantly higher for the 671
ELTS non-high-risk patients. For 56% of 1197 patients the
allocation of high-risk by the Sokal score was inappropriate.
Of 3037 patients identified as low-risk by the ELTS score,
the Sokal score classified 1200 (40%) as non-low-risk. The
cumulative incidences of dying of CML were only slightly
different from those of the remaining 1837 low-risk
patients, pointing to another inappropriate classification by
the Sokal score. However, in relation to the 1837 patients
assessed as low-risk by both scores, OS was significantly
lower. Nevertheless, at 92% after 6 years (95% CI:
90–94%) and 88% after 9 years (95% CI: 84–92%), OS
probabilities were still high for the 1200 Sokal non-low-risk
patients.
HRs and concordance indices showed the best prognostic
discrimination in the unbiased comparisons in the 2949
independent patients. Since the ELTS score was developed
in the 2205 in-study patients, their inclusion in the total
sample of 5154 patients meant some advantage for the
ELTS score compared with the other scores. The extent of
this limitation cannot be quantified, but in consideration of
the very distinctive results, it is still fair to conclude that the
risk of inappropriate classification is decidedly higher with
the Sokal score.
Successful validation of the ELTS score and superiority
in comparison with other scores were also reported by
Geelen et al [24]. In 709 patients with first-line imatinib
treatment, only the ELTS score was able to identify three
pairwise significantly different risk groups with respect to
OS and to achievement of a first major molecular response.
With only 23 deaths after progression, the ELTS score also
provided satisfactory differences in cumulative incidences
of death due to CML, but numbers were too low to allow a
reliable assessment of prognostic performance. Molica et al.
compared the four prognostic systems in 459 individuals
treated with imatinib as first-line TKI [8]. Of 51 deaths, only
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Fig. 6 Overall survival probabilities in 5154 patients from the
combined in-study, out-study, and population-based registry sec-
tions. a Stratified for the risk groups according to the ELTS score and
b with the 3037 low-risk patients according to the ELTS score stra-
tified for low-risk and non-low-risk according to the Sokal Score. At 3,
6, and 9 years, horizontal crossbars indicate the upper and lower limit
of the 95% confidence interval (CI) for the estimated probability.
a The intermediate- and high-risk groups of the ELTS score had sig-
nificantly lower survival probabilities than the low-risk group with
both P < 0.0001. The corresponding hazard ratios were 2.631 (95% CI:
2.116–3.273) and 3.675 (95% CI: 2.861–4.720). The concordance
indices at 1, 5, and 10 years were 66.6, 63.8, and 63.7, respectively.
b The non-low-risk group identified by the Sokal score had sig-
nificantly lower survival probabilities than the low-risk group
according to both scores, P= 0.0147. The corresponding hazard ratio
was 1.490 (95% CI: 1.082–2.053). The concordance indices at 1, 5,
and 10 years were 49.8, 54.4, and 54.4, respectively.
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ten were assessed as CML related. The authors judged
that the ELTS score predicted probabilities of death
better than the other scores. While Yang et al. observed the
most distinct risk group discrimination of OS probabilities
with the ELTS score in 462 imatinib-treated Chinese
patients with a median follow-up of 69 months [25], Millot
et al. found that its three risk groups differed significantly
from each other with respect to progression-free survival in
350 children with imatinib as first-line treatment—despite
only 23 events (progression or death) [26]. In both studies,
the authors concluded that the ELTS score outperformed all
other scores [25, 26]. However, instead of the conventional
Sokal score, Millot et al. considered the Sokal score for
younger patients (≤45 years) [26, 27].
In 202 Italian patients ≥65 years treated with imatinib or
nilotinib, in contrast to the Sokal score, the ELTS score
provided significant discrimination of the three risk groups
regarding major (BCR-ABL1 ≤ 0.1%, international scale,
IS) and deep molecular remission (BCR-ABL1 ≤ 0.01%, IS)
and the probabilities of leukemia-related deaths [28]. The
ELTS score also worked best when applied to 258 patients
diagnosed in advanced phase [29]. Lauseker et al. con-
cluded that the ELTS score could be applied to distinguish
long-term survival between high-risk and non-high-risk
patients until a better model developed in patients with
accelerated phase and/or blast crisis is introduced [29].
The ELTS score has been validated several times for its
ability to significantly discriminate risk groups regarding
long-term survival outcome but mainly in patients first-line
treated with imatinib [6, 8, 15, 24–26, 28]. Despite sig-
nificantly faster achievement of molecular reponses with
second generation TKIs [10, 13, 30–33], first-line treatment
with imatinib and its generics is still widespread. Most
physicians continue to see room for first-line treatment with
imatinib depending on age, comorbidities, kinase domain
mutations, treatment goal, costs, and availability of generic
imatinib [1, 33–37]. In prognostic support of first-line
treatment selection, the ELTS score offers the most appro-
priate risk group classification. This is also of interest as
imatinib has fewer side effects than second generation TKIs,
and it is perceived that a statistically significant overall
superiority in long-term efficacy over imatinib has not yet
been shown for another TKI [1, 33, 36, 37]. There is
indication that the ELTS score would also discriminate risk
groups with respect to long-term survival if a second gen-
eration TKI were chosen as first-line treatment [24]. More
evidence is needed. A large patient sample would be
necessary to recognize significant differences in long-term
survival between TKIs within a certain risk group.
Regarding risk group discrimination, the ELTS score
outperformed the Sokal score, the Euro, and the EUTOS
score. Due to our large patient sample, it was possible to
show, for the first time with statistical significance, that the
Sokal score is much more likely to provide an incorrect risk
group classification. The mechanism behind the superiority
of the ELTS score is its development in imatinib-treated
patients and its different weighting of the four prognostic
factors, together with a more adequate patient distribution
into risk groups (about 60%/30%/10%) than the Sokal score
(about 40%/40%/20%) in times when patients have much
better survival prospects due to TKIs.
In the most recently published ELN recommendations,
the panel recommend the use of the ELTS score as the
preferred method to assess baseline CML risk. Through our
work, we back the ELN recommendation with statistical
evidence. A valid score and its common application support
comparative assessment of efficacy and safety. The ELTS
score can be calculated via the “Hematology app” or the
website: https://www.leukemia-net.org/content/leukemias/
cml/elts_score.
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